ADDED
(A) (A) Excludes 43.8 million shares of common stock held by directors and executive officers, and any stockholders known to us whose ownership exceeded ten percent of our common stock outstanding as of June 30, 2025.
Bank National Association), as trustee, as supplemented by the First Supplemental Indenture, dated November 13, 2019, between Cytokinetics and U.S.
Bank National Association) 2026 Notes Cytokinetics 4% convertible senior notes due 2026 2027 Indenture Indenture, dated July 6, 2022, between Cytokinetics and U.S.
Bank Trust Company, as trustee 2027 Notes Cytokinetics 3.50% convertible senior notes due 2027 2031 Indenture Indenture, dated September 19, 2025, between Cytokinetics and U.S.
Food and Drug Administration Final Payment Amount As defined in Part II, Item 7 (Management s Discussion and Analysis of Financial Conditions and Results of Operations) of this Annual Report on Form 10-K Sources and Uses of Cash, Royalty Pharma Transactions FOREST-HCM Five-Year, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM Fundamental Change As defined in the 2026 Indenture, 2027 Indenture, or 2031 Indenture, as applicable GAAP Generally Accepted Accounting Principles in the U.S.
1, dated January 7, 2022 RP Stock Purchase Agreement Common Stock Option and Purchase Agreement, dated May 22, 2024, by and between Cytokinetics and Royalty Pharma Investments 2019 ICAV RPDF Royalty Pharma Development Funding, LLC RPFT RPI Finance Trust RPI ICAV Royalty Pharma Investments 2019 ICAV RSU Restricted Stock Unit Sanofi Means Sanofi S.A.
and/or any affiliates thereof, including Genzyme Corporation Sanofi License Agreement Means that certain License and Collaboration Agreement, dated July 14, 2020 by and between the Company and Sanofi (as assignee of Corxel), pursuant to which Sanofi has an exclusive license to develop and commercialize aficamten in China and Taiwan Section 382 Section 382 of the Internal Revenue Code Securities Act Securities Act of 1933, as amended SEQUOIA-HCM Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM SGLT2 Sodium-glucose cotransporter-2 U.S.
All statements other than statements of historical fact, including statements concerning our plans, objectives, goals, strategies, future events, future revenues or performance, financing needs, expectations, plans or intentions relating to clinical development, product candidates, the regulatory approval process, our commercialization efforts for MYQORZO, products and markets, and business trends and other information referred to under the Risk Factors and Management s Discussion and Analysis of Financial Condition and Results of Operations, are forward-looking statements.
In some cases, you can identify forward-looking statements by terms such as anticipate, assume, believe, commitment, could, estimate, expect, forecast, intend, may, plan, potential, predict, project, should, target, will, would, seek and similar expressions intended to identify forward-looking statements.
We have made these statements in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
REMOVED
(A) (A) Excludes 13.7 million shares of common stock held by directors and executive officers, and any stockholders whose ownership exceeds ten percent of the shares outstanding, at June 28, 2024.
Food and Drug Administration Final Payment Amount As defined in Part II, Item 7 (Management s Discussion and Analysis of Financial Conditions and Results of Operations) of this Annual Report on Form 10-K Sources and Uses of Cash, Royalty Pharma Transactions FOREST-HCM Five-Year, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM FSTA fast skeletal muscle troponin activator Fundamental Change As defined in the 2027 Indenture GAAP Generally Accepted Accounting Principles in the U.S.
1, dated January 7, 2022 RP Stock Purchase Agreement Common Stock Option and Purchase Agreement, dated May 22, 2024, by and between Cytokinetics and Royalty Pharma Investments 2019 ICAV RPDF Royalty Pharma Development Funding, LLC RPFT RPI Finance Trust RPI ICAV Royalty Pharma Investments 2019 ICAV RSU Restricted Stock Unit RTW ICAV RTW Investments ICAV for RTW Fund 1 RTW Investors RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd.
We intend that such statements be protected by the safe harbor created thereby.
Forward-looking statements involve risks and uncertainties and our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements.
Our research continues to drive innovation and leadership in muscle biology.
All of our drug candidates have arisen from our cytoskeletal research activities.
Corporate Strategy As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
Our goal is to identify or discover, develop and commercialize novel drug products that modulate muscle function to improve patient healthspan, with the intent of establishing a fully-integrated specialty biopharmaceutical company.
The key components of our five-year corporate strategy are: INNOVATION: Advance 2 product approvals across 3 indications and 10 novel molecular entities into our pipeline Our myosin platform is the cornerstone of our innovation and the anchor of our portfolio of potential medicines is aficamten, a cardiac myosin inhibitor that represents a next-in-class potential treatment for oHCM.